SBIR/STTR Research Award
Therapy for gastrointestinal disorders
Award amount
$0Program and phase
STTR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AGENNIX, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Applicant's Abstract): The overall goal of this research proposal
is to determine the effectiveness of recombinant human lactoferrin (rhLF) for
treating gastrointestinal (GI) disorders. This Phase II proposal will focus on
the ability of rhLF to treat the 01 side effects of non-steroidal
anti-inflammatory drugs (NSAIDs), a class of drugs widely-used for reduction of
pain, fever, and inflammation. The adverse GI side effects of ulceration and
bleeding limit the usefulness of NSAIDs. Recombinant human lactoferrin,
produced in high purity by advanced technological means, has a unique
combination of antibiotic, anti-inflammatory. and mucosal healing properties
that make it especially useful for the reduction of NSAID toxicity. The
specific aims of this proposal are to use animal models to determine: 1) the
efficacy of rhLF to prevent acute and chronic NSAID-induced GI side effects; 2)
the ability of rhLF to heal GI lesions that are aggravated by NSAIDs; and 3)
the mechanism for rhLF protection of the 0! tract in the presence of NSAIDs.
Development of this therapeutic potential for rhLF will fulfill a crucial need
for a way to safely administer NSAIDs.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
Technology keywords
Not reported